Showing 6301-6310 of 8773 results for "".
- Picato Approved in European Unionhttps://practicaldermatology.com/news/20121119-picato_approved_in_european_union/2459677/The European Commission has granted marketing authorization for LEO Pharma's Picato (ingenol mebutate) gel for the treatment of actinic keratosis in the European Union (EU). Picato was approved in the US earlier this year.
- Sun Pharmaceutical to Buy DUSA Pharmaceuticalshttps://practicaldermatology.com/news/20121118-sun_pharmaceutical_to_buy_dusa_pharmaceuticals/2459678/Sun Pharmaceutical Industries Ltd. will buy DUSA Pharmaceuticals Inc. for about $215 million in cash, as the India-based company looks to make a foray into the lucrative market for dermatological treatments. The deal has been unanimously approved by the boards of both companies and DUSA's board has
- Dermatology Partnerships Exploredhttps://practicaldermatology.com/news/20121115-dermatology_partnerships_explored/2459681/Research and Markets has added the "Dermatology Partnering Terms and Agreements" report to their offering. This report provides a detailed understanding and analysis of how and why companies enter dermatology
- "Cirque du CeraVe" Event in NYC Launches New CeraVe Productshttps://practicaldermatology.com/news/20121031-cirque_du_cerave_event_in_nyc_launches_new_cerave_products/2459687/The “Cirque du CeraVe” skincare launch event, held at Osteria del Circo in New York City on October, was attended by consumer, trade and dermatology media, who learned about new CeraVe product launches. The brand staged a CeraVe “Circus” complete with a professional mime, juggler, contortionist and
- Provectus Presents Data on PV-10 in Combination with Systemic Chemotherapyhttps://practicaldermatology.com/news/20121029-provectus_presents_data_on_pv-10_in_combination_with_systemic_chemotherapy/2459688/Provectus Pharmaceuticals, Inc. presented nonclinical data on PV-10 at the Society for Immunotherapy of Cancer (SITC) 27th Annual Meeting on October 26 and 27, 2012 in North Bethesda, MD. PV-10 is Provectus Pharmaceuticals' novel oncology drug design
- LEO Pharma's Taclonex Topical Suspension Approved for Body Plaqueshttps://practicaldermatology.com/news/20121029-leo_pharma_receives_fda_approval_for_taclonex_topical_suspension/2459689/LEO Pharma Inc. announced the US Food and Drug Administration (FDA) approval of Taclonex (calcipotriene and betamethasone dipropionate) Topical Suspension, 0.005%/0.064% for the treatment of body plaque psoriasis. Taclonex® Topical Suspension is
- Health-Conscious Women 60% More Likely to Prefer Expensive Brand-Name Drugshttps://practicaldermatology.com/news/20121025-health-conscious_women_60_more_likely_to_prefer_expensive_brand-name_drugs/2459691/The consumer market research firm Scarborough analyzed "Health-Conscious Women," defined by Scarborough as American adult women who agree that they go to the doctor regularly for checkups, generally feel they eat right, and follow a regular exercise routine. Health-Conscious Women make up 16 percent
- Serum adipokines and T-helper 17-related Cytokines Associated in Psoriasishttps://practicaldermatology.com/news/20121025-serum_adipokines_and_t-helper_17-related_cytokines_associated_in_psoriasis/2459692/New research suggests that adipokines and Th17 cytokines are involved in the pathogenesis of psoriasis. (Clin Exp Dermatol, E-pub) In patients with psoriasis, resistin levels were significantly positively associated with tumour necrosis factor-α, and there was a strong negative association between r
- ADCS Clinics Adds New Providers in Floridahttps://practicaldermatology.com/news/20121024-adcs_clinics_adds_new_providers_in_florida/2459694/After announcing a major acquisition of multiple clinics on Florida's West Coast, Advanced Dermatology & Cosmetic Surgery (ADCS) has acquired multiple practices throughout Florida. ADCS has added six new dermatologists to the practi
- Suneva Medical Completes Initial Treatment in Phase 3 Acne Scar Studyhttps://practicaldermatology.com/news/20121024-suneva_medical_completes_initial_treatment_in_phase_3_acne_scar_study/2459695/Suneva Medical, Inc. announced that it has completed the enrollment and initial treatment of patients in its Phase 3 acne scar study. This multi-center, prospective study is investigating the efficacy of Artefill for the treatment of moderate to